Nantahala Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Nantahala Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.1M	Hold	254,803	–	–	0.37%	69
2025 Q4	$6.37M	Sell	254,803 -150,000	-37%	-$3.8M	0.21%	94
2025 Q3	$9.82M	Sell	404,803 -150,000	-27%	-$2.67M	0.34%	68
2025 Q2	$7.29M	Hold	554,803	–	–	0.29%	68
2025 Q1	$7.98M	Buy	554,803 +42,156	+8%	+$690K	0.32%	51
2024 Q4	$8.59M	Hold	512,647	–	–	0.37%	52
2024 Q3	$8.2M	Buy	512,647 +62,647	+14%	+$767K	0.41%	50
2024 Q2	$4.06M	Buy	+450,000	New	+$4.27M	0.24%	71

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Nantahala Capital Management's CNTA Position: Q1 2026 in Review

Nantahala Capital Management held its Centessa Pharmaceuticals (CNTA) position steady in Q1 2026 at 254,803 shares worth $10.1M. The position accounts for 0.37% of the portfolio, ranked #69.

Nantahala Capital Management first reported a position in CNTA in Q2 2024 and has held it in 8 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

Nantahala Capital Management held 254,803 shares of Centessa Pharmaceuticals worth $10.1M as of Q1 2026.
Nantahala Capital Management left its Centessa Pharmaceuticals share count unchanged in Q1 2026.
Centessa Pharmaceuticals made up 0.37% of Nantahala Capital Management's portfolio in Q1 2026, its #69 holding.
Nantahala Capital Management first reported a position in Centessa Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.